Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 5, 2000, Pages 81-91

  Massy, Z A ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINO ACID DERIVATIVE; AMINOGUANIDINE; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; BEZAFIBRATE; CORTICOTROPIN; CYANOCOBALAMIN; DEXTROTHYROXINE; FIBRINOGEN; FOLIC ACID; GLYCOPROTEIN; HOMOCYSTEINE; IMIDAZOLE DERIVATIVE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LYSINE DERIVATIVE; METHIONINE; NANDROLONE; PENTOSIDINE; PLASMINOGEN; POLYPEPTIDE; PYRIDOXINE; STEROID;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; KIDNEY DISEASE; MALE; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SEROPREVALENCE; THROMBOEMBOLISM; UREMIA;

EID: 0033787074     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.suppl_5.81     Document Type: Article

References (148)

1. Homocysteine and cardiovascular disease
2. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease-probable benefits of increasing folic acid intakes
3. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
4. Serum total homocysteine and coronary heart disease
5. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project
6. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
7. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
8. Homocysteine and risk of cardiovascular disease in the multiple risk factor intervention trial
9. Plasma homocysteine levels and mortality in patients with coronary artery disease
10. Meta-analysis of hyperhomocysteinaemia as a risk factor for venous thromboembolic disease
11. MTHFR association with arterio-sclerotic vascular disease?
12. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
13. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
14. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease
15. Homocysteine, diet, and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee, American Heart Association
16. Serum homocysteine level and protein intake are related to risk of microalbuminuria: The Hoorn Study
17. Increased plasma homocysteine concentration in patients with chronic renal failure
18. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
19. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure
20. Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid
21. Kinetic basis of hyperhomocysteinaemia in patients with chronic renal failure
22. Incidence and risk factors of atherosclerotic cardiovascular accidents in pre-dialysis chronic renal failure patients: A prospective study
23. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease
24. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure
25. Sustained reduction of hyperhomocysteinaemia with folic acid in predialysis patients
26. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
27. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
28. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
29. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
30. Hyperhomocysteinaemia in renal failure - What are the implications?
31. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study
32. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
33. High dose B-vitamin treatment of hyperhomocysteinaemia in dialysis patients
34. Folic acid treatment of hyperhomocysteinemia in dialysis patients
35. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in hemodialysis patients
36. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
37. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy
38. Short-term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation
39. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemo-dialysis patients
40. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
41. Endothelium-dependent vasodilation is impaired in peritoneal dialysis patients
42. Major determinants of hyperhomocysteinaemia in peritoneal dialysis patients
43. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
44. Dialysis adequacy and homocysteine concentrations in peritoneal dialysis patients
45. Oral or parental therapy for B12 deficiency
46. Metabolism of B6 and its requirement in chronic renal failure
47. Lipoprotein(a) in health and disease
48. Proteolytic modifications of lipoprotein(a): Potential relevance to its postulated atherothrombogenic role
49. Lp(a) levels in different types of dyslipidemia in the French population
50. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels
51. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
52. Lipoprotein(a) as a risk factor for ischemic heart disease: Meta analysis of prospective studies
53. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The quebec cardiovascular study
54. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans
55. A prospective case control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City project participants
56. Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case control study
57. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease
58. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension
59. Therapy for lowering lipoprotein (a) levels
60. Elevated lipoprotein (a) levels in primary nephrotic syndrome
61. Lipoprotein(a) in patients with proteinuria
62. Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome
63. Lipoprotein(a) in nephrotic syndrome
64. A study of the clinical significance of lipoprotein(a) in nephrotic syndrome
65. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: Relation to remission of proteinuria
66. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome
67. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome
68. Improvement of lipid abnormalities associated with proteinuria using fosinopril, and angiotensin-converting enzyme inhibitor
69. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria
70. Serum lipoprotein (a) concentration is increased in moderate renal failure
71. Serum Lp(a) levels in patients with moderate renal failure
72. Serum lipoprotein (a) levels in chronic renal failure and renal transplant patients
73. Increased lipoprotein(a) concentrations in chronic renal failure
74. Increased serum lipoprotein(a) levels in patients with early renal failure
75. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function
76. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
77. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation
78. Localization of apolipoprotein (a) and B-100 in various renal diseases
79. Plasma levels of lipoprotein(a) do not predict progression of human chronic renal failure
80. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome
81. Reduction of lipoprotein (a) following treatment with lovastatin in patients with unremitting nephrotic syndrome
82. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease
83. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein (a)
84. Multicenter study of lipopotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
85. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus
86. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein (a) genetic polymorphism
87. Lipoprotein(a) levels in hemodialysis patients: Relation to glucose intolerance and hemodialysis duration
88. Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis
89. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: Implications for plasma Lp(a) assay
90. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease
91. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients
92. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction
93. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
94. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis
95. Lipoprotein (a) in chronic renal failure patients undergoing hemodialysis: Does it have an independent role in the development of further cardiovascular complications?
96. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy
97. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predict coronary artery disease in hemodialysis patients
98. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients
99. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects
100. LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients
101. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease
102. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up
103. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients
104. Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: Relation to apolipoprotein(a) size polymorphism
105. D-Thyroxine reduces lipoprotein(a) serum concentration in dialysis patients
106. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients
107. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients
108. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD
109. Genetic regulation of fibrinogen
110. Influence of fibrinogen on cardiovascular disease
111. Beyond coagulation: Fibrinogen as a cause of cardiovascular surgical disease
112. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
113. Fibrinogen is an independent marker for thoracic aortic atherosclerosis
114. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?
115. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease
116. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress
117. Plasma protein abnormalities in nephrotic syndrome: Effect on plasma colloid osmotic pressure and viscosity
118. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: Measurements with stable isotopes
119. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease
120. Carotid artery lesions in patients with nondiabetic chronic renal failure
121. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure
122. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
123. Erythrocyte sedimentation rate, an underestimated tool in chronic renal failure
124. Effect of renal replacement therapy on viscosity in end-stage renal disease patients
125. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
126. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease
127. Hyperhomocysteinaemia, hyperfibrinogenaemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
128. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: A case control study using quantitative coronary angiography
129. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis
130. Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis
131. Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients
132. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin
133. Elevated lipoprotein(a) and fibrinogen levels [corrected] increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients
134. Advanced glycation end products, oxidant stress and vascular lesions
135. Advanced glycosylation end products in diabetic renal and vascular disease
136. Nε-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins
137. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody
138. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs
139. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus
140. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications
141. Advanced glycosylation end products in patients with diabetic nephropathy
142. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure
143. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients
144. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation
145. Immunohistochemical detection of imidazolone and N(ε-(carboxymethyl) lysine in aortas of hemodialysis patients
146. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease
147. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia
148. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'